Karyopharm Therapeutics Stock Buy Hold or Sell Recommendation
| KPTI Stock | USD 0.85 0.03 3.41% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding Karyopharm Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Karyopharm Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Karyopharm Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide. In addition, we conduct extensive research on individual companies such as Karyopharm and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Karyopharm |
Execute Karyopharm Therapeutics Buy or Sell Advice
The Karyopharm recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Karyopharm Therapeutics. Macroaxis does not own or have any residual interests in Karyopharm Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Karyopharm Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Karyopharm Therapeutics Trading Alerts and Improvement Suggestions
| Karyopharm Therapeutics had very high historical volatility over the last 90 days | |
| Karyopharm Therapeutics has some characteristics of a very speculative penny stock | |
| Karyopharm Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 146.03 M. Net Loss for the year was (143.1 M) with profit before overhead, payroll, taxes, and interest of 151.86 M. | |
| Karyopharm Therapeutics currently holds about 170.85 M in cash with (92.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Karyopharm Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Karyopharm Therapeutics SWOT analysis oncology stock faces pivotal trials |
Karyopharm Therapeutics Returns Distribution Density
The distribution of Karyopharm Therapeutics' historical returns is an attempt to chart the uncertainty of Karyopharm Therapeutics' future price movements. The chart of the probability distribution of Karyopharm Therapeutics daily returns describes the distribution of returns around its average expected value. We use Karyopharm Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Karyopharm Therapeutics returns is essential to provide solid investment advice for Karyopharm Therapeutics.
| Mean Return | 0.26 | Value At Risk | -8.43 | Potential Upside | 12.68 | Standard Deviation | 5.18 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Karyopharm Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Karyopharm Stock Institutional Investors
| Shares | Cam Group Holding A/s | 2024-09-30 | 1.5 M | Jpmorgan Chase & Co | 2024-09-30 | 1.4 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-09-30 | 1.3 M | Deutsche Bank Ag | 2024-06-30 | 1.3 M | Millennium Management Llc | 2024-09-30 | 1.3 M | Renaissance Technologies Corp | 2024-09-30 | 1.2 M | Kennedy Capital Management Inc | 2024-09-30 | 1.2 M | Ubs O'connor Llc | 2024-09-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 7.7 M | Eversept Partners, Llc | 2024-09-30 | 5.5 M |
Karyopharm Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 12.0M | (41.6M) | 108.3M | (60.6M) | (83.7M) | (79.5M) | |
| Free Cash Flow | (191.0M) | (160.4M) | (112.8M) | (149.7M) | (92.7M) | (97.4M) | |
| Depreciation | 974K | 972K | 789K | 621K | 530K | 622.5K | |
| Capital Expenditures | 2.4M | 206K | 145K | 5.7M | 118K | 0.0 | |
| Net Income | (199.6M) | (196.3M) | (124.1M) | (165.3M) | (143.1M) | (150.3M) | |
| End Period Cash Flow | 130.7M | 89.1M | 197.4M | 136.9M | 53.2M | 102.9M | |
| Other Non Cash Items | 7.2M | 8.4M | 8.1M | (294K) | (3.3M) | (3.1M) | |
| Change To Netincome | 15.3M | 24.2M | 37.0M | 35.1M | 40.4M | 22.7M | |
| Investments | 78.7M | (53.5M) | 147.6M | (104.1M) | (84.2M) | (80.0M) |
Karyopharm Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Karyopharm Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Karyopharm Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Karyopharm stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 1.00 | |
σ | Overall volatility | 5.20 | |
Ir | Information ratio | 0.02 |
Karyopharm Therapeutics Volatility Alert
Karyopharm Therapeutics shows above-average downside volatility for the selected time horizon. Karyopharm Therapeutics is a potential penny stock. Although Karyopharm Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Karyopharm Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Karyopharm instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Karyopharm Therapeutics Fundamentals Vs Peers
Comparing Karyopharm Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Karyopharm Therapeutics' direct or indirect competition across all of the common fundamentals between Karyopharm Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Karyopharm Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Karyopharm Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Karyopharm Therapeutics to competition |
Note: Disposition of 3592 shares by Paulson Richard A. of Karyopharm Therapeutics at 0.99 subject to Rule 16b-3 [view details]
Karyopharm Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Karyopharm . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Karyopharm Therapeutics Buy or Sell Advice
When is the right time to buy or sell Karyopharm Therapeutics? Buying financial instruments such as Karyopharm Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Karyopharm Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Equity ETFs Thematic Idea Now
Broad Equity ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Karyopharm Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.